Life after failure of traditional androgen deprivation therapy

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4 SUPPL., 2012, Pages

  Schellhammer, Paul ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Androgen biosynthesis inhibitors; Anti androgens; Castrate resistant prostate cancer; Estrogen

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CALCIUM CHANNEL BLOCKING AGENT; DENOSUMAB; DOCETAXEL; ERYTHROMYCIN; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; NILUTAMIDE; PARACETAMOL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SEROTONIN UPTAKE INHIBITOR; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; FLUID RETENTION; HUMAN; HYPERTENSION; HYPOKALEMIA; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RECEPTORS, ANDROGEN;

EID: 84863822661     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.01.009     Document Type: Review

References (19)

1. Davis J.W., Schellhammer P.F. Clinical signs and symptoms of prostate cancer. Comprehensive textbook of genitourinary oncology 2006, Lippincott Williams & Wilkins. 3rd ed. N.J. Vogelzang, P.T. Scardino, W.U. Shipley, F. Debruyne, W.M. Linehan (Eds.).
2. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials. Lancet 2000, 355:1491-1498. Prostate Cancer Trialists Collaborative Group.
3. Klotz L., Schellhammer P., Carroll K. A reassessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004, 93:1177-1182.
4. Akaza H., Hinotsu S., Usami M., et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009, 115:3437-3445.
5. Rosner W., Vesper H., et al. Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: A consensus statement. J Clin Endocrinol Metab 2010, 95:4542-4548. Endocrine Society, American Association for Clinical Chemistry, American Association of Clinical Endocrinologists, Androgen Excess/PCOS Society, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, American Urological Association.
6. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010, 60:194-201.
7. Mohler J.L., Gregory C.W., Ford O.H., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004, 10:440-448.
8. Montgomery R.B., Mostaghel E.A., Vessella R., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008, 68:4447-4454.
9. Morote J., Orsola A., Planas J., et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007, 178:1290-1295.
10. Perachino M., Cavalli V., Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance?. BJU Int 2010, 105:648-651.
11. Attard G., Reid A.H., de Bono J.S. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010, 28:e560-e561.
12. Danila D.C., Morris M.J., de Bono J.S., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated, castration-resistant prostate cancer. J Clin Oncol 2010, 28:1496-1501.
13. Reid A.H., Attard G., Danila D.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28:1489-1495.
14. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005. COU-AA-301 investigators.
15. Klotz L. A phase III randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK intercontinental trial CRUKE/01/013. ASCO Genitourinary Cancers Symposium. J Clin Oncol 2011, 29(Suppl 7). Abstract 43. Presented 2011, Abstract 3.
16. Scher H.I., Beer T.M., Higano C.S., et al. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC). Proceedings of the ASCO Genitourin Cancers Symposium 2009, Abstract 151.
17. Byar D.P., Corle D.K. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988, 7:165-170.
18. Ockrim J.L., Lalani E.N., Banks L.M., et al. Transdermal estradiol improve bone density when used as single agent therapy for prostate cancer. J Urol 2004, 172:203-207.
19. Wibowo E., Schellhammer P., Wassersug R.J. Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol 2011, 185:17-23.